Background: A subset of melanomas carrying a B-Raf proto-oncogene, serine/threonine kinase gene (BRAF ) V600E mutation, which is the most common targetable mutation in melanoma, arise in association with a melanocytic nevus that is also harboring a BRAF V600E mutation. The detailed histomorphologic characteristics of nevi positive for BRAF V600E have not been systematically documented.
Melanocytic nevi are exceedingly common benign melanocytic neoplasms on which biopsies are commonly performed. They are mimics, risk factors, and precursors of melanoma, which is the deadliest of the common forms of skin cancer. The most common genetic driver and therapeutically targetable mutation in melanoma is the V600E mutation of the B-Raf proto-oncogene, serine/threonine kinase gene (BRAF ), which is a gene encoding a serine/threonine kinase in the RAS/ mitogen-activated protein kinase pathway. [1] [2] [3] [4] [5] Notably, BRAF mutations are found in more than 80% of melanocytic nevi, 2, 6, 7 including a subset of melanocytic nevi that act as precursors for melanoma. 8, 9 It is therefore paramount to better define the clinical, histomorphologic, and genetic features of melanocytic nevi that may predict progression to or association with melanoma.
In melanoma, the presence of the BRAF V600E mutation correlates with certain clinicopathologic findings, including age younger than 55 years and intermittent sun exposure, as well as with histopathologic features of intraepidermal upward scatter of melanocytes, nest formation of intraepidermal melanocytes, thickening of the epidermis, and larger tumor cells. 10 Similarly, melanocytic nevi with a BRAF V600E mutation are of earlier onset. 11 Additionally, these nevi are associated with a globular dermoscopic pattern and a predominantly dermal histologic growth pattern. 1, 6, [12] [13] [14] Although these results are based on relatively small data sets, 6 they suggest that the BRAF V600E mutation may affect the characteristics and behavior of nevi.
The diagnosis of melanoma is based on histologic examination. In a subset of cases, the histologic distinction between a nevus and a melanoma is challenging. Therefore, there is a growing interest in the development of novel molecular diagnostic tests and classification systems based on the combination of histomorphologic and molecular features. To expand our knowledge of the morphologic-genetic correlation in melanocytic nevi, we retrospectively identified 150 melanocytic nevi and performed a detailed histomorphologic analysis and BRAF V600E immunohistochemistry to identify morphologic features correlating with BRAF V600E status.
MATERIALS AND METHODS

Cases
This study was approved by the institutional review board of the University of California, Davis (No. 756049). Pathology archives were searched from January 2014 to March 2014 for histologically proven melanocytic nevi, 150 of which were included in this study. To ensure that the cohort consisted of common nevi, dysplastic nevi, and nevi with congenital pattern, we included 30 consecutive cases identified by using the search term junctional melanocytic nevus; 30 consecutive cases identified by using the search terms compound melanocytic nevus, predominantly intradermal melanocytic nevus, and intradermal melanocytic nevus; 30 consecutive cases identified by using the search term nevus, congenital pattern; 30 consecutive cases identified by using the search term junctional melanocytic nevus, dysplastic type; and 30 consecutive cases identified by using the search term compound melanocytic nevus, dysplastic type. Exclusion criteria included the diagnosis of a blue nevus, a Spitz nevus, or a nevus with unusual or atypical growth.
Histomorphologic analysis
Hematoxylin-eosinestained slides and tissue blocks were available for 135 cases. The hematoxylineosinestained slides were reviewed by 1 or 2 board-certified dermatopathologists (M.K. and M.F.) before the availability of the BRAF V600E staining results. The following parameters were recorded: dermal growth pattern, congenital pattern, nesting of intraepidermal melanocytes, size of junctional nests, epidermal contour, lateral circumscription, pigmentation, cell size, cytologic atypia, pagetoid melanocytes, architectural disorder, inflammatory infiltrate, and solar elastosis. The detailed criteria for each category are described in Table I . 10, [15] [16] [17] [18] [19] BRAF V600E immunohistochemistry BRAF V600E expression was analyzed by immunohistochemistry using previously described conditions with minor modifications. 20 
Whole exome sequencing
Tumor tissue was manually microdissected from formalin-fixed paraffin-embedded tissue sections. DNA was isolated by using standard protocols. Whole exome sequencing analysis, including analysis of the BRAF gene, was performed by nextgeneration sequencing (Novogene, Sacramento, CA) to an average read depth of more than 100 3 by using the HiSeq 4000 sequencing system (Illumina, San Diego, CA). Raw sequence reads were aligned to the reference human genome (GRCh37) and variants were identified by using a DRAGEN hardware/software server platform utilizing a field-programmable gate array pipeline (for details of the DRAGEN server and methods see Miller et al 22 ).
Statistical analysis
Descriptive statistics were stratified by BRAF V600E status, with mean and standard deviation (SD) for continuous variables and by count and percent for categorical variables. Two-sample t tests were used to compare means between BRAF V600E groups. Chi-square tests were used to examine associations between categorical variables and Fisher exact tests if any cell size was less than 5. For those with all cell sizes of 5 or more, logistic regression models were used to study the association between a binary histomorphologic feature and BRAF V600E status, whereas multinomial logistic regression models were used for associations with a categorical histomorphologic feature of more than 2 levels.
RESULTS
Patient characteristics and the results of histomorphologic and immunohistochemical staining are shown in Table II The mean age was 53.5 years (SD, 11.3) for patients with nevi negative for BRAF V600E and 48.0 (SD, 16.7) for patients with nevi positive for BRAF V600E (P = .26). The ratio of males to females was 1:1.6 for patients with nevi negative for BRAF V600E and 1:2.3 for patients with nevi positive for BRAF V600E (P = .56). The distribution of the anatomic locations of head/neck, trunk, and extremity (extremity includes hand or foot) was similar in both groups: 7.7%, 53.9%, and 38.5%, respectively, for nevi negative for BRAF V600E and 13.3%, 52.0%, and 34.7%, respectively, for nevi positive for BRAF V600E.
Significant associations were found between the histomorphologic features of nevi and BRAF V600E expression. A predominantly junctional growth pattern was associated with nevi negative for BRAF V600E (11 of 13 [84.6%]) (Fig 1, A and B) , whereas nevi positive for BRAF V600E showed a predominantly dermal growth pattern (42 of 76 [55.3%]) (P = .01) (Fig 1, C and D) . Furthermore, in contrast to nevi positive for BRAF V600E (39 of 76 or [51.3%]), only 2 of the 13 nevi negative for BRAF V600E (15.4%) displayed congenital features, which were defined as adnexal and/or periadnexal growth, perivascular growth, and/or splaying of melanocytes among collagen fibers (P = .02) (Fig 1 E and F ) . Additionally, differences in many other histomorphologic variables were noted; however, they did not reach statistical significance in this data set. These differences included nesting of intraepidermal melanocytes (predominantly nested intraepidermal melanocytes in 16.7% of nevi negative for BRAF V600E vs in 39.3% of nevi positive for BRAF V600E) and size of junctional nests (medium to large nests in 16.7% of nevi negative for BRAF V600E vs in 43.6% of nevi positive for BRAF V600E), and lateral circumscription (abrupt borders in 15.4% of nevi negative for BRAF V600E vs in 40% of nevi positive for BRAF V600E). Additionally, architectural disorder (present in 61.5% of nevi negative for BRAF V600E vs in 44.7% of nevi positive for BRAF V600E) and inflammatory infiltrates (present in 76.9% of nevi negative for BRAF V600E vs in 50% of nevi positive for BRAF V600E) were more frequently observed in nevi negative for BRAF V600E. Finally, although no differences were observed in the presence of cytologic atypia, cell size appeared larger in nevi positive for BRAF V600E (large cell size in 23.1% of nevi negative for BRAF V600E vs in 47.4% of nevi positive for BRAF V600E). BRAF gene sequencing was performed in 4 cases in a blinded fashion (ie, without knowledge of the results of the immunohistochemistry before analysis of the sequencing data). Two nevi that were negative for BRAF V600E by immunohistochemical staining were negative for BRAF mutations, whereas 2 nevi with a positive BRAF V600E staining result showed BRAF chr7:140453136A[T (BRAF V600E) mutations. No other recurrent somatic mutations were identified.
DISCUSSION
Our study shows that the histomorphologic features of a melanocytic nevus can yield meaningful information on the mutation status of BRAF, which is the most common genetic driver of melanocytic tumors. We have demonstrated that melanocytic nevi with BRAF V600E expression are more likely to show a predominantly dermal growth pattern and congenital features. Additionally, nevi positive for BRAF V600E often exhibit predominantly nested intraepidermal melanocytes, medium to large junctional nests, abrupt lateral circumscription, and larger cell size. By contrast, architectural disorder and the presence of an inflammatory infiltrate are more often seen in a nevus negative for BRAF V600E. These results validate prior studies showing a correlation between dermal growth and BRAF V600E status. 1, 6, [12] [13] [14] Furthermore, the findings of this study expand the knowledge of genotype-phenotype correlation in melanocytic tumors, potentially facilitating a more accurate and comprehensive classification of melanocytic tumors. 10 Our findings are consistent with prior results on the frequency of BRAF V600E in melanocytic nevi, 2, 6, 7 the predominance of a compound or dermal growth pattern in these tumors, 1, 6, 7, [12] [13] [14] 23 and the association with large junctional nests. 6 In our data set, BRAF V600E was expressed in 86% of melanocytic nevi. A compound or predominantly dermal growth pattern was seen in 55.3% of nevi positive for BRAF V600E, whereas only 15.4% of nevi negative for BRAF V600E were compound or predominantly dermal. In prior studies, 63% to 84.6% of nevi positive for BRAF V600E were intradermal, 51% to 82% were compound, and 2% to 35% were junctional. 1, 7, 12 According to prior J AM ACAD DERMATOL VOLUME 79, NUMBER 2 studies, BRAF V600E is frequent not only in common acquired and dysplastic nevi but also in congenital nevi. 7, 13 We have further demonstrated that congenital features can in fact serve as another distinguishing finding between nevi positive for BRAF V600E and nevi negative for BRAF V600E; in our series, such features were present in 51.3% of nevi positive for BRAF V600E and 15.4% of nevi negative for BRAF V600E. Of note, similar to cases in prior studies, the cases with BRAF V600E expression and congenital features in our study were typically small nevi and not clinically confirmed large congenital nevi, which typically show an NRAS proto-oncogene, GTPase gene (NRAS ) mutation instead of BRAF V600E (reviewed in Roh et al 24 ). As pointed out by Viros et al, 10 who studied the associations between morphologic and genetic features in melanoma, genotype-phenotype correlation may allow generation of hypotheses on the function or role of the gene in the biology of tumor type. Notably, the benign melanocytic tumors with BRAF V600E that were examined in this study share many features with their malignant counterparts studied by Viros et al 10 (namely, nest formation of intraepidermal melanocytes, sharper demarcation from the surrounding skin, and larger tumor cells). This finding suggests an overlap of phenotypic effects shared by benign and malignant melanocytic tumors associated with a mutant BRAF gene.
Nevi positive for BRAF V600E can serve as precursors to melanoma. 25 Borderline lesions, and possibly also dysplastic nevi, appear to contain other drivers such as the NRAS gene. In our series, architectural disorder and inflammation, which are some of the hallmarks of a dysplastic nevus, were less common in nevi positive for BRAF V600E than in nevi negative for BRAF V600E. Further work is needed to establish whether a characteristic genotype exists for dysplastic nevi and to identify genetic drivers of nevi negative for BRAF and NRAS.
The criterion standard for the diagnosis of melanoma is histologic examination. In a subset of melanocytic tumors (typically in up to 10% but on the basis of some reports, in as many as 25% of cases), 26 the histologic distinction between melanoma and nevus is problematic if not impossible. [26] [27] [28] As early diagnosis significantly increases rates of survival of melanoma, improving diagnostic accuracy is imperative and may require ancillary molecular testing. Understanding the genetic pathway of early melanomagenesis, such as but likely not limited to telomerase reverse transcriptase gene (TERT ) promoter mutations and p16 loss, 25 is required to identify clinically useful markers and predictors of malignant transformation.
CONCLUSIONS
Our study demonstrates that the histomorphologic features of a melanocytic nevus can provide relevant information on its molecular background, including the presence of BRAF V600E, which is the most common driver of melanocytic tumors and the most common therapeutically targetable alteration in melanoma. A greater understanding of the genotype-phenotype correlation in melanocytic nevi may facilitate the development of a more accurate classification system for melanocytic tumors that ultimately leads to improved diagnostic accuracy and management of these exceedingly common human tumors, as well as to a better understanding of markers and predictors of malignant transformation.
